Am J Epidemiol 2002; 156:397-401.
Copyright © 2002 by the
Johns Hopkins Bloomberg School of Public Health
ORIGINAL CONTRIBUTIONS |
Epidemiology and Survival Analysis of Cystic Fibrosis in an Area of Intense Neonatal Screening Over 30 Years
1 Cystic Fibrosis Center, Verona, Italy.
2 Department of Pediatrics, University of Milano Medical School, Milano, Italy.
3 Department of Clinical Medicine, Prevention and Biotechnologies, Section of Medical Statistics, University Milano-Bicocca, Milano, Italy.
This population-based study was conducted in Veneto and Trentino (northwestern Italy, population 5 million). In this area, neonatal screening for cystic fibrosis started in 1973 and has been virtually universal since the early 1980s. During this study, the estimated incidence of cystic fibrosis in this region was 1/2,650 livebirths per year. The authors analyzed data on 593 patients born in 1938–2000 and living in the region who were followed by a single referral center. Median time from birth to confirmation of diagnosis after screening was 32 days (range, 0–1,531). For patients whose disease was recognized after symptoms occurred, median age at diagnosis was always less than 1 year. Median survival age was 37.7 years. Long-term survival (to age 20–30 years) was not significantly influenced by mode of diagnosis (screened or unscreened), sex, or age at diagnosis for unscreened patients (<1, 1–5, >5 years). Current survival analysis of three consecutive decades showed that improving survival tended to vanish in the last years of the study. The authors concluded that a regional neonatal screening program allows very early recognition of cystic fibrosis. They could not conclude that neonatal screening improves long-term survival if compared with diagnosis by symptoms in early infancy.
cystic fibrosis; neonatal screening; survival analysis
Abbreviations: Abbreviations: IRT, immunoreactive trypsinogen; SE, standard error.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Donadieu, C. Roudier, M. Saguintaah, C. Maccia, and R. Chiron Estimation of the Radiation Dose From Thoracic CT Scans in a Cystic Fibrosis Population Chest, October 1, 2007; 132(4): 1233 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Comeau, F. J. Accurso, T. B. White, P. W. Campbell III, G. Hoffman, R. B. Parad, B. S. Wilfond, M. Rosenfeld, M. K. Sontag, J. Massie, et al. Guidelines for Implementation of Cystic Fibrosis Newborn Screening Programs: Cystic Fibrosis Foundation Workshop Report Pediatrics, February 1, 2007; 119(2): e495 - e518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. van den Akker-van Marle, H. M. Dankert, P. H. Verkerk, and J. E. Dankert-Roelse Cost-effectiveness of 4 Neonatal Screening Strategies for Cystic Fibrosis Pediatrics, September 1, 2006; 118(3): 896 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Comeau, R. B. Parad, H. L. Dorkin, M. Dovey, R. Gerstle, K. Haver, A. Lapey, B. P. O'Sullivan, D. A. Waltz, R. G. Zwerdling, et al. Population-Based Newborn Screening for Genetic Disorders When Multiple Mutation DNA Testing Is Incorporated: A Cystic Fibrosis Newborn Screening Model Demonstrating Increased Sensitivity but More Carrier Detections Pediatrics, June 1, 2004; 113(6): 1573 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Lai, Y. Cheng, H. Cho, M. R. Kosorok, and P. M. Farrell Association between Initial Disease Presentation, Lung Disease Outcomes, and Survival in Patients with Cystic Fibrosis Am. J. Epidemiol., March 15, 2004; 159(6): 537 - 546. [Abstract] [Full Text] [PDF]
|
|